Drug Search Results
More Filters [+]

Avotermin

Alternative Names: avotermin
Latest Update: 2024-03-05
Latest Update Note: PubMed Publication

Product Description

Avotermin, the first agent identified in this class, is the clinical application of human recombinant transforming growth factor beta3 (TGFbeta3), a key protein involved in scar-free healing observed in embryos.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18757391/)

Mechanisms of Action: TGFR Inhibitor

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Topical,Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Renovo
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Avotermin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Vision, Low|Depressive Disorder

Phase 2: Healthy Volunteers|Vision, Low|Injuries/wounds Unspecified|Keloid|Burns Unspecified|Varicose Veins|Nevus

Phase 1: Healthy Volunteers|Lymphoma|Injuries/wounds Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

KOHDIAK

P1

Not yet recruiting

Lymphoma

2021-02-01

Juvista in the prevention or reduction of the resultant scar following scar revision surgery.

P2

Completed

Burns Unspecified|Vision, Low

2011-03-03

Juvista in scar revision surgery of disfiguring scars

P3

Completed

Vision, Low

2011-01-30

Revise

P3

Completed

Vision, Low|Depressive Disorder

2011-01-01

Recent News Events